Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients
Sponsor: Ajinomoto USA, INC.
This PHASE2/PHASE3 trial investigates Diabetes Mellitus, Type II and Type 2 Diabetes Mellitus and is currently completed. Ajinomoto USA, INC. leads this study, which shows 6 recorded versions since 2026 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2_PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Ajinomoto USA, INC.
- Astellas Pharma Inc
For direct contact, visit the study record on ClinicalTrials.gov .